Possibly, but why would they buy IMU when they can buy Allogene for nothing. Allogene has a market cap of US$258m, but they have US$335m in cash. While this seems like a bargain, they are spending US$60m a quarter with US$50m on R&D. By comparison IMU is very efficient and frugal, but IMU investors should study at Allogene to understand how expensive pivotal cell therapy trials are.
Allogene do share something with IMU - their SP is down 97.5% from their peak.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $112.0M | |||
| Open | High | Low | Value | Volume |
| 1.5¢ | 1.6¢ | 1.4¢ | $125.4K | 8.369M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 76 | 17029463 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.5¢ | 1061875 | 3 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |